Abstract: A method can determine Attention-Deficit Hyperactivity Disorder (ADHD) and/or evaluate the prognosis and/or determine the effectiveness of a therapy against ADHD. The method is based on measuring the methylation levels of CpG dinucleotides and/or CpG islands in a genomic region of the SLC6A3 gene (solute carrier family 6 member 3), preferably in the 5? UTR.
Type:
Application
Filed:
December 21, 2017
Publication date:
June 11, 2020
Applicants:
Istituto Superiore di Sanita', Universita' degli Studi di Teramo, Universita' degli Studi di Roma "La Sapienza"
Inventors:
Giovanni LAVIOLA, Walter ADRIANI, Esterina PASCALE, Claudio D'ADDARIO
Abstract: The present invention relates to the synthesis and characterization of biotinylated analogue of N-arachidonoylethanolamine (AEA) and its use as a tool to study AEA transport and trafficking through biochemical and morphological techniques. In particular biotinylated AEA (b-AEA, for which we propose the common name MM22) is suitable to design highly sensitive and simple methods for the non-radioactive detection and quantitation of AEA from complex samples, which would offer a useful alternative approach to the routinely used radiometric assays. The invention also relates to the use of b-AEA as a potential therapeutic and diagnostic agent.
Type:
Grant
Filed:
May 2, 2006
Date of Patent:
June 7, 2011
Assignees:
Universita Degli Studi Di Roma “Tor Vergata”, Universita Degli Studi Di Teramo
Abstract: The present invention relates to the synthesis and characterisation of biotinylated analogue of N-arachidonoylethanolamine (AEA) and its use as a tool to study AEA transport and trafficking through biochemical and morphological techniques. In particular biotinylated AEA (b-AEA, for which we propose the common name MM22) is suitable to design highly sensitive and simple methods for the non-radioactive detection and quantitation of AEA from complex samples, which would offer a useful alternative approach to the routinely used radiometric assays. The invention also relates to the use of b-AEA as a potential therapeutic and diagnostic agent.
Type:
Application
Filed:
May 2, 2006
Publication date:
May 7, 2009
Applicants:
UNIVERSITA' DEGLI STUDI DI ROMA "TOR VERGATA", UNIVERSITA' DEGLI STUDI DI TERAMO